Camelot Portfolios, LLC Gilead Sciences, Inc. Transaction History

Camelot Portfolios, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$63.15 - $72.88 $4,988 - $5,757	79 New	79 $5,000
Q4 2022 Jan 25, 2023	SELL	$62.32 - $89.47 $140,905 - $202,291	-2,261 Reduced 40.25%	3,356 $0
Q3 2022 Oct 31, 2022	SELL	$59.54 - $68.01 $95,085 - $108,611	-1,597 Reduced 22.14%	5,617 $347,000
Q2 2022 Jul 18, 2022	BUY	$57.72 - $65.01 $106,724 - $120,203	1,849 Added 34.46%	7,214 $446,000
Q1 2022 Apr 20, 2022	SELL	$57.92 - $72.58 $194,379 - $243,578	-3,356 Reduced 38.48%	5,365 $319,000
Q4 2021 Jan 04, 2022	BUY	$64.88 - $73.64 $55,602 - $63,109	857 Added 10.9%	8,721 $633,000
Q3 2021 Nov 04, 2021	SELL	$67.69 - $73.03 $81,972 - $88,439	-1,211 Reduced 13.34%	7,864 $549,000
Q2 2021 Jul 28, 2021	BUY	$63.47 - $69.35 $575,990 - $629,351	9,075 New	9,075 $625,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Camelot Portfolios, LLC, based on Form 13F filings with the SEC.

Stay updated on Camelot Portfolios, LLC with notifications on news.